Ebenbuild receives 2.5 million euros

The healthtech now plans to further develop its lung simulation prototype and seek approval as a medical device.

The healthtech Ebenbuild has closed a seed financing round of 2.5 million euros. High-Tech Gründerfonds and Bayern Capital, the venture capital company of the Free State of Bavaria, jointly led the round. In addition, several business angels participated in the start-up. Ebenebuild had already announced in February that it was close to closing a financing round worth millions.

Kei Müller, Jonas Biehler, Wolfgang Wall and Karl-Robert Wichmann founded Ebenbuild in 2019, having previously researched a better treatment for acute respiratory distress syndrome at the Technical University in Munich. This often occurs after other illnesses and is often fatal. Together, the researchers developed software that creates simulation models of lungs based on patient data. With the help of the simulations, physicians can then put together an individualized treatment for their patients.

"We are convinced that after years of preparation and more than 15 years of cutting-edge international research, we can now envisage clinical use with our product," says Ebenbuild founder and CEO Kei Müller. With the financial resources from the financing round, Ebenbuild intends to further develop its prototype and seek approval as a medical device.